Drugs / RD140
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06655519 | Oct 2024 → Jul 2028 expected | plasma cell leukemia, refractory plasma cell neoplasm | Peking University People's Hospital | Not yet recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-09-25 | Nanjing IASO Biotechnology Co., Ltd. | 2026 IMS | IASO Bio Presents First-in-Human Phase 1 Data of RD140, a Fully Human BCMA/GPRC5D Dual-Targeted FasT CAR-T iasobio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RD140 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06655519 ↗ |
| Modality | Cell therapy | “Chimeric Antigen Receptor T Cells” NCT06655519 ↗ |
| Target | GPRC5D | “Fully Human Anti-BCMA/GPRC5D Chimeric Antigen Receptor T Cells” NCT06655519 ↗ |